Bharti Airtel likely to show improvement in Q2; revenue may rise 17% YoY

Emkay says the company's India wireless revenues shall rise sequentially, boosted by a 43 lakh increase in data subscribers against the stable data subs in the last quarter.

Telecom major Bharti Airtel will announce its September quarter scorecard on October 27 and brokerages expect the company to show some improvement in its numbers.

Emkay Global expects Bharti Airtel's net sales to see a 17 percent year-on-year (YoY) growth while EBITDA and EBITDA margin may rise 21.9 percent and 177 bps YoY, respectively, due to coronavirus-related cost-saving in SG&A coming back in the base.

The company's India wireless revenues shall rise sequentially, boosted by a 43 lakh increase in data subscribers against the stable data subs in the last quarter, the brokerage said.

Emkay expects ARPU to rise 1 percent quarter-on-quarter (QoQ) despite a seasonally weak quarter, accompanied by the return of some voice subscribers in the base.

"Data volume shall continue to accrue benefits of the lockdown and rise 7.5 percent QoQ, while MOU shall see a decline due to seasonality," Emkay said.

The Africa business, as per Emkay Global, should witness a 3 percent sequential revenue rise on the back of a low base due to currency devaluation.

Motilal Oswal Financial Services expects Airtel's ARPU to largely remain flat. It foresees a 4 percent subscriber growth in home broadband and 3 percent revenue growth in enterprise business.

As per Motilal's estimates, the company's adjusted PAT for Q2FY21 may come at Rs 300 crore against a loss of Rs 1,100 crore in Q2FY20. Revenue may see a 16 percent YoY jump.

Brokerage firm Kotak Institutional Equities expects a 15.1 percent YoY jump in the company's net sales.

Kotak said as offline recharge activity is likely to have improved (after the COVID-led disruption in the previous quarter), it expects reported subs to be higher by 29 lakh QoQ.

"We build in a 1.2 percent QoQ (up 21.5 percent YoY) increase in implied ARPU," Kotak said.

For the Africa business, Kotak expects a flat quarter sequentially (up 8.6 percent YoY) on a reported basis.

"Among the other businesses, we expect 4 percent QoQ growth in revenues for the home broadband, 3 percent QoQ growth for the enterprise business, and 2 percent QoQ growth in the DTH business," Kotak said.

Source - Moneycontrol.com

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

SD Solutions

Search This Blog